Publications, Projects & Awards

Full listing of articles published by VHIO investigators in 2019
Selection of some of the most relevant articles by VHIO researchers
Scientific productivity: research articles

Cellular Plasticity & Cancer Group

Principal Investigator Maria Abad Post-Doctoral Fellow Elena Senis Graduate Students Olga Boix, Alba Escriche, Emanuela Greco, Marion Martinez, Iñaki Merino Research Assistant Mireia Jimenez Technician Marta Gimenez

Awards and Recognition

  • We were awarded with the Health Research Grant 2018 from the La Caixa Foundation.
  • We also received the Health Research Grant from La Mutua Madrileña Foundation.

Projects

  1. Defining the Role of Exosome-Secreted Micropeptides in Pancreatic Cancer. number: HR18-00256.Health Research Grant-La Caixa Foundation.
    Award Period: 9/2019-8/2021.
    PI: Maria Abad.
  2. Identificación y Análisis del Microproteoma del Cáncer de Páncreas: Los Micropéptidos como Nuevas Dianas Terapéuticas y Biomarcadores Tumorales Fundación. XVI Convocatoria de Ayudas a la Investigación en Salud. Fundación Mutua Madrileña.
    01/09/2019-30/08/2022.
    PI: Maria Abad.
  3. Mining the Microproteome for New Molecular Targets in Cancer. number: RTI2018-102046-B-I00.Spanish Ministry of Economy and Competitiveness.
    1/2019-12/2021.
    PI: Maria Abad.
  4. Cellular Plasticity in Tissue Regeneration and Cancer. Ref. number: RYC-2013-14747.
    Spanish Ministry of Economy and Competitiveness.
    Award Period: 9/2015-8/2020.
    PI: Maria Abad.

Chromatin Dynamics in Cancer Group

Principal Investigator Sandra Peiró Post-Doctoral Fellows Laura Pascual, Gemma Serra Graduate Students Marc Cosin, Carmen Escudero, Queralt Serra Students Josep Francesch, Laura Mondejar, Macarena Palacios Technician Jessica Querol

Publications

  • Cebrià-Costa JP, Pascual-Reguant L, Gonzalez-Perez A, Serra-Bardenys G, Querol J, Cosín M, Verde G, Cigliano RA, Sanseverino W, Segura-Bayona S, Iturbide A, Andreu D, Nuciforo P, Bernado-Morales C, Rodilla V, Arribas J, Yelamos J, de Herreros AG, Stracker TH, Peiró S. LOXL2-mediated H3K4 oxidation reduced chromatin accessibility in triple negative breast cancer cells. Oncogene. 2020 Jan;39(1):79-121. Epub 2019 Aug 28.

Projects

  1. Identificación y caracterización de nuevos elementos reguladores durante la adquisición de competencias metastásicas en un modelo de transición epitelio-mesénquima y en tumores de mama triple-negativos.
    Spanish Carlos III Health Institute (FIS)
    2019–2022
  2. .
  3. Epigenetic Landscape Characterization of Cholangiocarcinomas.
    Fundació Marató TV3
    2020–2023
  4. .

Experimental Therapeutics Group

Principal Investigator Violeta Serra Post-Doctoral Fellows Alba Llop-Guevara, Marta Palafox, Mónica Sánchez Graduate Students Marta Castroviejo, Laia Monserrat, Flaminia Pedretti Visiting Students Alais Marie Berthod, Andreu Odena, María Jimena Rodríguez Technicians Judit Grueso, Marta Guzmán, Andrea Herencia, Mireia Pares, Olga Rodríguez

Publications

  • Pellegrino B, Mateo J, Serra V, Balmaña J. Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making? ESMO Open. 2019 May 9;4(2):e000480.
  • Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. A decade of clinical development of PARP inhibitors in perspective. Ann. Oncol. 2019 Sep 1;30(9):1437-1447.
  • Gourley C, Balmaña J, Ledermann JA, Serra V, Dent R, Loibl S, Pujade-Lauraine E, Boulton SJ. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. J. Clin. Oncol. 2019 Sep 1;37(25):2257-2269.
  • Green JL, Okerberg ES, Sejd J, Palafox M, Monserrat L, Alemayehu S, Wu J, Sykes M, Aban A, Serra V, Nomanbhoy T. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs. Mol. Cancer Ther. 2019 Apr;18(4):771-779.

Awards and Recognition

  • Our Principal Investigator, Violeta Serra – along with Judith Balmaña, PI of VHIO’s Hereditary Cancer Genetics Group- received  the very first joint FERO-GHD Award in 2019. This funding will spur research into developing liquid biopsy to monitor response to therapy and establish the sensitivity of breast cancer patients with BRCA1/2 mutations to treatment with PARP inhibitors. The goal is to more effectively tailor personalized treatment regimens to the unique specificities of each particular cancer, more effectively tackle cancer drug resistance, as well as establish which patients would be most likely to benefit from these targeted therapies.
  • Violeta Serra received La Marató funding to investigate mechanisms of resistance to therapy with PARP inhibitors (PARPi). By liquid biopsy, Violeta’s team will aim to establish whether the RAD51 biomarker, that can predict sensitivity to PARPi, can more effectively identify the patients who will be most likely to benefit.

Projects

New projects awarded in 2019, commencing in 2020:
  1. RAD51predict: Patient stratification based on DNA repair functionality for cancer precision medicine(ERAPERMED2019-215).
    Funding Agency: ERA Net
    Coordinator: Violeta Serra
    Duration: 2020-2022
  2. Liquid biopsies for the identification of mechanisms of resistance to PARP inhibitors in BRCA1/2-associated cancers (654/C/2019).
    Funding Agency: La Marató TV3
    Coordinator: Violeta Serra
    Duration: 2020-2022
Projects awarded/initiated in 2019:
  1. Development of a liquid biopsy test to assess the homologous recombination function status in BRCA1/2 mutation carriers with breast cancer to inform therapy selection.
    Funding Agency: FERO Foundation
    Principal Investigator: Violeta Serra
    Duration: 2019-2020
  2. Modulation of androgen receptor signalling as a therapeutic strategy for oestrogen receptor-positive metastatic breast cancer(2018NovPCC1291).
    Funding Agency: Breast Cancer Now
    Principal Investigator: Violeta Serra
    Duration: 2019-2021
Other ongoing projects:
  1. Targeted agents against PARP, WEE1, ATR and ATM in TNBC: mechanisms of action, biomarkers of sensitivity and immunomodulation (PI17/01080).
    Funding Agency: ISCIII
    Principal Investigator: Violeta Serra
    Duration: 2018-2020
  2. New predictive factors of response to targeted therapies and prognostic factors in breast cancer with germline mutations in BRCA1 and BRCA2: DNA damage repair capacity and tumor immunological profile (LABAE16020PORT).
    Funding Agency: AECC (Spanish Association Against Cancer)
    Principal Investigator: Violeta Serra
    Duration: 2018-2020

Gene Expression & Cancer Group

Principal Investigator Joan Seoane Post-Doctoral Fellows Ester Bonfill, Laura Escudero, Raffaella Iurlaro, Monica Pascual, Ester Planas, Carlota Rubio, Research Fellow, Davide Ciardiello Masters Student Samia Hajem Graduate Student Ester Arroba Technicians Alexandra Arias, Mª Isabel Cuartas, Alba Martinez

Publications

  • Pascual-GarcíaM, Bonfill-TeixidorE, Planas-RigolE, Rubio-PerezC, IurlaroR,AriasA, Cuartas I, Sala-HojmanA, Escudero E, Martínez-Ricarte F, Huber-Ruano I, NuciforoP, PedrosaL, MarquesC, BrañaI, GarraldaE, VieitoM, SquatritoM, PinedaE, GrausF, EspejoC, SahuquilloJ, TaberneroJ, SeoaneJ. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+T cell tumor-infiltration impairing anti-PD1 therapy. Nat Commun. 2019 Jun 11;10(1):2416.
  • SeoaneJ, De Mattos-ArrudaL, Le RhunE, BardelliA, WellerM. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann Oncol. 2019 Feb 1;30(2):211-218.
  • Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A. How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019 Oct 1;30(10):1580-1590.
  • De Mattos-Arruda L, Sammut SJ, Ross EM, Bashford-Rogers R, Greenstein E, Markus H, Morganella S, Teng Y, Maruvka Y, Pereira B, Rueda OM, Chin SF, Contente-Cuomo T, Mayor R, Arias A, Ali HR, Cope W, Tiezzi D, Dariush A, Dias Amarante T, Reshef D, Ciriaco N, Martinez-Saez E, Peg V, Ramon Y Cajal S, Cortes J, Vassiliou G, Getz G, Nik-Zainal S, Murtaza M, Friedman N, Markowetz F, Seoane J, Caldas C.The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer. Cell Rep. 2019 May 28;27(9):2690-2708.

Awards and Recognition

  • Joan Seoane was awarded by the Ramón Areces Foundation in 2019 to seek out novel immunotherapeutic targets in brain metastases.

    In multidisciplinary collaboration with Enriqueta Felip, PI of VHIO’s Thoracic Tumors & Head and Neck Cancer Group, and Eva Muñoz, Clinical Investigator of our Breast Cancer & Melanoma Group (PI: Cristina Saura), he will analyze patients’ brain metastases and compare them with respective primary tumors to reveal factors governing clinical response to immune checkpoint blockade.

Projects

  1. Grantor: Fundación Científica de la AECC
    Title:  Study of the molecular mechanisms involved in primary (glioblastoma) and secondary (metastasis) brain tumors to identify novel therapeutic targets and anti-cancer agents, biomarkers to select treatments and novel non-invasive methods for molecular diagnosis.

    Project Reference: GCTRA16015SEDA
    Role in the Project: Principal Investigator
    2017-2022.
  2. Grantor: IBEC-La Caixa
    Title: Understanding and measuring mechanical tumor properties to improve cancer diagnosis, treatment, and survival: Application to liquid biopsies
    Project Reference:
    Role in the Project: Principal Investigator
    2017-2020.
  3. Grantor: Institute of Health Carlos III – FIS (Ministry of Science and Innovation-MICINN) Title:Identificación de mecanismos de resistencia a tratamiento a través del estudio de la heterogeneidad intra-tumoral en glioblastoma
    Project Reference: Ref. PI16/01278
    Role in the project: Principal Investigator
    2017-2019.
  4. Institute of Health Carlos III – Sara Borrell
    Title: Papel de LIF y TDFb en la regulación del sistema inmunológico en glioblastoma y metástasis cerebrales
    Project Reference: CD18/00223
    Role in the project: Principal Investigator
    2019-2021.
  5. Ramon Areces Foundation.
    Title: Identification of novel immunotherapeutic targets in lung and melanoma brain metastases.
    Project reference: CIVP19A5943
    Role in the Project: Principal Investigator
    2019-2022.
  6. FERO
    Title: Caracterización molecular mediante el estudio del ADN circulante en líquido cefalorraquídeo para la mejora del tratamiento del tumor cerebral pediátrico, meduloblastoma
    2019-2020.

Growth Factors Group

Principal Investigator Joaquín Arribas Post-Doctoral Fellows Enrique Javier Arenas, Cristina Bernado, Faiz Bilal, Beatriz Morancho, Irene Rius, Veronica Rodilla Graduate Students Luis Alfonso Garcia, Alejandro Martinez-Sabadell, Macarena Roman Students Jose Angel Palomeque, Daniel Fernando Pilco, Carlos Ramirez, Federica Zanotti Technicians Marta Escorihuela, Beatriz Martin, Antonio Miguel Luque

Publications

  1. Triana-Martínez F, Picallos-Rabina P, Da Silva-Álvarez S, Pietrocola F, Llanos S, Rodilla V, Soprano E, Pedrosa P, Ferreirós A, Barradas M, Hernández-González F, Lalinde M, Prats N, Bernadó C, González P, Gómez M, Ikonomopoulou MP, Fernández-Marcos PJ, García-Caballero T, Del Pino P, Arribas J, Vidal A, González-Barcia M, Serrano M, Loza MI, Domínguez E, Collado M. Identification and characterization of Cardiac Glycosides as senolytic compounds. (2019) Nat Commun. 10(1):4731. doi: 10.1038/s41467-019-12888-x.
  2. Cebrià-Costa , J. P., Pascual-Reguant, L., Gonzalez-Pérez ,A., Serra-Bardenys , G., Querol , J., Cosin, M., Verde, G., Cigliano, RA., Sanseverino, W., Segura-Bayona S, Iturbide A, Andreu , D., Nuciforo, P., Bernadó-Morales, C.,  Rodilla V, Arribas, J., Yelamos J, de Herreros, A.G, Stracker TH, Peiró S. LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple negative breast cancer cells.  (2019) Oncogene. 2019 Aug 28. doi: 10.1038/s41388-019-0969-1.
  3. Gomez-Miragaya, J., Díaz-Navarro, A., Tonda, R., Beltran, S., Palomero, L., Palafox, M., Dobrolecki, L., Vasaikar, S., Huang, C., Zhang, B., Wulf, G., Muñoz, P., Paré, L., Serra, V., Prat, A., Bruna, A., Caldas, C., Arribas, J., Balmaña, J., Cruz, C., Pujana, M. A., Lewis, M., Puente, X., Gonzalez-Suarez, E. Chromosome 12p amplification in triple-negative breast cancer is associated with emergent docetaxel resistance and carboplatin sensitivity (2019) Cancer Research79, 4258-4270.
  4. Merlino, G., Fiascarelli, A., Bigioni, M., Bressan, A., Carrisi, C., Bellarosa, D., Salerno, M., Bugianesi, R., Manno, R., Bernadó Morales, C., Arribas, J., Dusek, R. L., Pham, P. H., Awdew, R., Aud, D. M., Trang, M., Terrett, J., Wilson, K. E., Rohlff, C., Manzin, S., Pellacani, A, Binaschi, M. MEN1309/OBT076, a first-in-class Antibody Drug Conjugate (ADC) targeting CD205 in solid tumors (2019) Mol Cancer Ther. 2019 Sep;18(9):1533-1543.
  5. Diaz-Rodriguez, E., Pérez-Peña, J., Ríos-Luci, C., Arribas, J., Ocaña, A., Pandiella, A. TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells (2019) Cancer Letters 453, 34-44.
  6. Gorbatenko, A., Søkilde, R., Sorensen, E. E., Newie, I., Persson, H., Morancho, B., Arribas, J., Litman, T., Rovira, C., Pedersen, S. F. HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503 (2019) Scientific Reports 9, 3352.
  7. Blasco-Benito S, Moreno E, Seijo-Vila M, Tundidor I, Andradas C, Caffarel MM, Caro-Villalobos M, Urigüen L, Diez-Alarcia R, Moreno-Bueno G, Hernández L, Manso L, Homar-Ruano P, McCormick PJ, Bibic L, Bernadó Morales C, Arribas J, Canals M, Casadó V, Canela EI, Guzmán M, Pérez-Gómez E, Sánchez C. Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer. (2019) Proc Natl Acad Sci U S A. 116(9) 3863-3872.
  8. Kang SA, Guan JS, Tan HJ, Chu T, Thike AA, Bernadó Morales C, Arribas J, Wong CY, Tan PH, Gudi M, Putti TC, Sohn J, Lim SH, Lee SC, Lim YP. Elevated WBP2 expression in HER2-positive breast cancers correlates with sensitivity to trastuzumab-based neo-adjuvant therapy:A Retrospective and Multicentric Study. Clin Cancer Res. 2019 Apr 15;25(8):2588-2600.
  9. Lambies G, Miceli M, Martínez-Guillamon C, Olivera-Salguero R, Peña R, Frías CP, Calderón I, Atanassov BS, Dent SYR, Arribas J, García de Herreros A, Díaz VM. TGFβ-activated USP27X deubiquitinase regulates cell migration and chemoresistance via stabilization of Snail1. (2019) Cancer Res. 2019 Jan 1. 79(1):33-46.

Projects

  1. Redirection of T cells against HER2-driven tumors.
    Asociación Española Contra el Cáncer (AECC). Grupos Coordinados AECC 2019.
    Coordinator: Joaquín Arribas
    2019-2024
  2. Immunotherapy against HER2 positive tumors. PI19/01181.
    Instituto Salud Carlos III (ISCIII).
    PI: Joaquín Arribas
    2020-2022
  3. Novel therapies against HER2-positive breast tumors: targeting oncogene-induced senescence and the immune system. BCRF-19-08. Breast Cancer Research Foundation (BCRF).
    PI Joaquín Arribas
    2019-2020
  4. Conjugados Anticuerpo-Droga contra HER2: Mecanismos de Resistencia y Combinaciones Terapéuticas.
    Fundación Mutua Madrileña.
    Co-PIs: Joaquín Arribas, Javier Cortés.
    2018-2021
  5. 754923. Horizon 2020 call SC1-PM-02-2017. Consortium 14 Partners.
    Coordinator: Annette Byrne.
    PI: Joaquín Arribas.
    2018-2023
  6. EDIReX: EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts. 731105. Horizon 2020 call H2020-INFRAIA 2016-2017.
    Consortium 19 Partners.
    Coordinator: Enzo Medico.
    PI: Joaquín Arribas.
    2018-2022
  7. Immunotherapy Against HER2-positive Breast and Gastric Cancers. PI16/00253. Instituto de Salud Carlos III.
    PI: Joaquín Arribas.
    2017-2019
  8. Novel therapies against HER2-positive breast tumors: targeting oncogene-induced senescence and the immune system. BCRF-18-008. Breast Cancer Research Foundation (BCRF).
    PI: Joaquín Arribas. 2018-2019
  9. Immunotherapy against p95HER2 positive breast cancer. 2016 PROD 00108. Fondos Europeos de Desarrollo Regional (FEDER) 2014-2020/Agencia de Gestió d’Ajuts Universitaris i de Recerca (AGAUR).
    PI: Joaquín Arribas.
    2017-2019
  10. CB16/12/00449. Instituto de Salud Carlos III.
    PI: Joaquín Arribas.
    2017-2020.

Mouse Models of Cancer Therapies Group

Principal Investigator Laura Soucek Staff Scientist Jonathan Whitfield Post-Doctoral Fellows Jastrinjan Kaur, Mariano F. Zacarias Graduate Student Sandra Martinez Technicians Virginia Castillo, Inmaculada Genesis Martin, Erika Serrano del Pozo Fulbright Scholar Jessica Lee Chambers

Awards and Recognition

  • As a key opinion leader in Myc and cancer, Laura Soucek was invited to write reviews, be guest editor for a special edition of Current Opinion in Pharmacology, and assemble an updated version of the Springer Nature Methods in Molecular Biology series book on Myc protocols.
  • She has also been appointed as Member of the Scientific Committee of the FERO Foundation, Spain.
  • Her scientific and entrepreneurial merits have also been recognized by the sportswear/equipment brandNIKEin Barcelona that selected her and Marie-Eve Beaulieu (first author of the Science Translational Medicinepaper in 2019) as model talents for science for the launch of their most recent FC Barcelona strip and merchandize campaign 2019.
  • Finally, Laura was presented with the European Award for Female Entrepreneurs by the Asociación Europea de Economía y Competitividadand won the FIDEM Award (International Foundation for Women Entrepreneurs) under the category for science.

Publications

  1. Ikemori R, Gabasa M, Duch P, Vizoso M, Bragado P, Arshakyan M, Luis IC, Marín A, Morán S, Castro M, Fuster G, Gea-Sorli S, Jauset T, Soucek L, Montuenga LM, Esteller M, Monsó E, Peinado VI, Gascon P, Fillat C, Hilberg F, Reguart N, Alcaraz J. Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma. Cancer Res. 2019 Nov 6.
  2. Pesarrodona M, Jauset T, Díaz-Riascos ZV, Sánchez-Chardi A, Beaulieu ME, Seras-Franzoso J, Sánchez-García L, Baltà-Foix R, Mancilla S, Fernández Y, Rinas U, Schwartz Jr S, Soucek L, Villaverde A, Abasolo I, Vázquez E. Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies. Adv Sci.  2019 Jul 24.
  3. Whitfield JR, Soucek L. Editorial Overview: Peptides in Cancer.  Curr Opin Pharmacol. 2019 Jun 27. pii: S1471-4892(19)30045-1.
  4. Ramón Y Cajal S, Sancho P, Soucek L, Peinado H, Abad M, Valiente M, Efeyan A, Pardo J, Quesada V, Jimeno J, Duque PM, Antón A, Varela I, Schuhmacher AJ. A spotlight on cancer researchers in Spain: new paradigms and disruptive ideas. Clin Transl Oncol. 2019 Aug 9.
  5. Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano del Pozo E, Fiore C, Foradada L, Castillo Cano V, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MA, Whitfield JR, Lavigne P, Soucek L.  Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-Myc therapy.Sci Trans Med.2019 Mar 20;11(484).
  6. Alimova I, Pierce A, Danis E, Donson A, Birks DK, Griesinger A, Foreman NK, Santi M, Soucek L, Venkataraman S, Vibhakar R. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1 deficient Group 2 Atypical Teratoid Rhabdoid Tumors to suppress tumor growth in vivo.Int J Cancer. 2019 Apr 15;144(8):1983-1995.

Projects

  1. Instituto de Salud Carlos III: Proyectos FIS de Investigación en Salud.
    Title: Validation of new anti-Myc therapy in Melanoma. 2020-2023.
    PI: Laura Soucek
    Awarded in 2019.
  2. Fundació La Marató de TV3.
    Title: Overcoming immunotherapeutic resistance through Myc inhibition in KRas-driven NSCLC with diverse mutational landscape.
    2020-2022.
    Project Director: Laura Soucek. Co-participant: Silvestre Vicent Cambra.
    Awarded in 2019.
  3. Canadian Institutes of Health Research Grant.
    Title:Development of cancer therapies targeting Myc with cell penetrating b-HLH-LZ domains.
    2018-2023.
    Role: Co-applicant.
  4. ERC (European Commission) Proof-of-Concept Grant.
    Title: Development of an effective and safe systemic Myc inhibitor for the treatment of multiple cancer types.
    2017-2019.
    PI: Laura Soucek
  5. H2020 INFRAIA 2017
    Grant: EDIReX: EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts.
    2017-2021.
    Role: Co-applicant
  6. Instituto de Salud Carlos III: Proyectos FIS de Investigación en Salud.
    Title: In vivo validation of innovative anti-Myc therapies in glioblastoma. 2016-2019.
    PI: Laura Soucek

Stem Cells & Cancer Group

Principal Investigator Héctor G. Palmer Post-Doctoral Fellows Oriol Arques, Estefania Cuesta, Jordi Martinez-Quintanilla, Isabel Puig Graduate Student Alex Mur Technicians Laia Cabellos, Irene Chicote, Lorena Ramirez Student Claudia Bigas

Publications

  1. Capdevila J, Arqués O, Hernández Mora JR, Matito J, Caratù G, Mancuso FM, Landolfi S, Barriuso J, Jimenez-Fonseca P, Lopez Lopez C, Garcia-Carbonero R, Hernando J, Matos I, Paolo N, Hernández-Losa J, Esteller M, Martínez-Cardús A, Tabernero J, Vivancos A, Palmer HG. Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas.Clin Cancer Res. 2020 Feb 15;26(4):902-909. doi: 10.1158/1078-0432.CCR-19-1266. Epub 2019 Oct 31.
  2. Capdevila J, Matos I, Mancuso FM, Iglesias C, Nuciforo P, Zafon C, Palmer HG, Ogbah Z, Muiños L, Hernando J, Villacampa G, Peña CE, Tabernero J, Brose MS, Schlumberger M, Vivancos A. Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial.Mol Cancer Ther. 2020 Jan;19(1):312-317. doi: 10.1158/1535-7163.MCT-19-0211. Epub 2019 Sep 20.
  3. Selenica P, Raj N, Kumar R, Brown DN, Arqués O, Reidy D, Klimstra D, Snuderl M, Serrano J, Palmer HG, Weigelt B, Reis-Filho JS, Scaltriti M. Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway.Mol Oncol. 2019 Aug;13(8):1684-1692. doi: 10.1002/1878-0261.12490. Epub 2019 Jul 3.

Projects

  1. Accelerator Award. Pseudomyxoma peritonei: building a European multicentric cohort to accelerate new therapeutic perspectives.
    Funding entities: Cancer Research UK (CRUK), Asociación Española contra el Cancer (AECC) & Associazione Italiana per la Ricerca sul Cancro (AIRC).
    2019-2024.
    PI: Héctor G. Palmer (Consortium Coordinator: Marcello Deraco).
  2. SCITRON. Discovering Mechanisms of Resistance to Anti-BRAFV600E-based therapies.
    Funding entity:Novartis International AG.
    2018-2020.
    PI: Héctor G. Palmer.
  3. ONIRIA: Modulating Cell Dormancy to Fight Cancer.
    Funding entity:Fundación Bancaria Caixa d’Estalvis i Pensions de Barcelona.
    2019-2020.
    PI: Héctor G. Palmer.
  4. Accelerator Award. ACRCelerate: Colorectal Cancer Stratified Medicine Network.
    Funding entities: Cancer Research UK (CRUK), Asociación Española contra el Cáncer (AECC) & Associazione Italina per la Ricerca sal Cancro (AIRC).
    2018-2021.
    PI: Héctor G. Palmer (Consortium Coordinator: Owen Sansom).
  5. Eider, EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts.
    Funding entity: EU Horizon2020 Research and Innovation Program.
    2018-2021.
    PI: Héctor G. Palmer (Consortium Coordinator: Enzo Medico).
  6. Studying the efficacy of BLU667 on axenograft model of papillary thyroid carcinoma with a NCOA4-RETfusion.
    Funding entity: Blueprint.
    2018-2020.
    PI: Héctor G. Palmer.
  7. Funding entity: Fundación de la Asociación Española Contra el Cáncer (AECC).
    2017-2021.
    PIs: Isabel Puig and Héctor G. Palmer.
  8. Anti-LGR5/EGFR bi-specific antibodies for the treatment of mCRC.
    Funding entity: MERUS.
    2016-2020.
    PI: Héctor G. Palmer.
  9. Cáncer de colon hipermutante - de su génesis y evolución genética a los tratamientos dirigidos contra dianas moleculares. PI17/00945.
    Funding entity: Instituto de Salud Carlos III.
    2016-2020.
    PI: Héctor G. Palmer.
  10. Refining mesothelin as therapeutic target in advanced colorectal cancer.
    Funding entity: Bayer Global.
    2017-2020.
    PIs: Héctor G. Palmer and Paolo Nuciforo.

Tumor Biomarkers Group

Principal Investigator Josep Villanueva Post-Doctoral Fellows Chiara Bellio Olga Méndez, Nathalie Meo-Evoli Graduate Student Mireia Pujals Technicians Mireia Pares, Candida Salvans, Gabriel Tamayo

Publications

  1. Méndez O, Pérez J, Soberino J, Racca F, Cortés J,  Villanueva J. Clinical Implications of Extracellular HMGA1 in Breast Cancer. Int J Mol Sci. 2019, 20(23), 5950.
  2. Arreal L, Piva M, Fernández S, Revandkar A, Schaub-Clerigué A, Villanueva J, Zabala-Letona A, Pujana M, Astobiza I, Cortazar AR, Hermanova I, Bozal-Basterra L, Arruabarrena-Aristorena A, Crespo JR, Valcarcel-Jimenez L, Zúñiga-García P, Canals F, Torrano V, Barrio R, Sutherland JD, Alimonti A, Martin-Martin N, Carracedo A.Targeting PML in triple negative breast cancer elicits growth suppression and senescence. Cell Death Differ. 2019 Oct 1. doi: 10.1038/s41418-019-0407-5.

Projects

  1. Characterization of HMGA1 as a mediator of tumor progression in breast cancer.
    Funding Agency: Pla estratègic de Recerca i Innovació en Salut (PERIS). Departament de Salut. Generalitat de Catalunya.
    Duration: 2017 – 2019.
    Recipient: Olga Méndez.
  2. Caracterización de HMGA1 como mediador de la progresión tumoral en el cáncer de mama.
    Funding Agency: Instituto de Salud Carlos III (ISCIII).
    Duration: 2016 – 2019.
  3. We are part of CIBERONC’s Programa de Tumores del Tracto Digestivo, as part of the group (Program ID: CB16/12/00259) led by VHIO’s Director and Head of our Gastrointestinal & Endocrine Tumors Group, Josep Tabernero (PI: Teresa Macarulla).